{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-089272","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.872488+00:00","generated_at":"2026-05-17T06:51:54.977839+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SELLAS raises $23.6M via warrant exercise; issues new 5.5-yr warrants at $1.88 strike","bullets":["Existing warrant holder cash exercises 19,685,040 shares at $1.20, yielding $23.6M gross proceeds.","In exchange, company issues new unregistered warrants to buy same number of shares at $1.88 (closing price Sep 10).","New warrants exercisable immediately, expire 5.5 years from issuance; resale registration statement to be filed within 30 days.","Company pays aggregate fee of 6.5% of gross proceeds to A.G.P. and Maxim Group as financial advisors.","90-day lock-up on share issuance and 12-month ban on variable-rate transactions included in inducement agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-089272","json":"https://secwatch.observer/filing/0001104659-25-089272.json","markdown":"https://secwatch.observer/filing/0001104659-25-089272.md","text":"https://secwatch.observer/filing/0001104659-25-089272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925089272/0001104659-25-089272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925089272/tm2525854d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:51:54.977839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13dbae942ef1f447b2a66fa96ef0aa19c029b87e","claim":"SELLAS Life Sciences Group, Inc. issued up to 19,685,040 shares of Common Stock of warrant to a holder for in consideration of the Holder’s agreement to exercise the Existing Warrants.","evidence_excerpt":"Pursuant to the Inducement Agreement, the Holder and the Company agreed that, subject to any applicable beneficial ownership limitations, the Holder would cash exercise 19,685,040 shares of Common Stock at an exercise price of $1.20 per share","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925089272/0001104659-25-089272-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to 19,685,040 shares of Common Stock"},{"label":"Purchaser","value":"a holder"},{"label":"Consideration","value":"in consideration of the Holder’s agreement to exercise the Existing Warrants"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}